[WSJ] UK Recommends Covering Sovaldi Hepatitis C Pill

The U.K. agency that evaluates the cost effectiveness of prescription drugs has recommended the government pay for the controversial Sovaldi hepatitis C treatment, although not for all patients.

The move, which still requires a final endorsement, comes as the medicine causes a ruckus in the U.S. The price tag–$84,000 for a 12-week regimen–has insurers and state Medicaid directors worried that the Gilead Sciences GILD +2.62% medication will become a budget buster and helped to fuel a national debate over the rising cost of prescription drugs.

[button title=”Read More” link=”http://blogs.wsj.com/pharmalot/2014/08/14/uk-recommends-covering-sovaldi-hepatitis-pill/” target=”_blank” size=”” color=”” class=””]